Views

CrossRef citations to date

Altmetric

Letters to the Editor

BCL2L12 protein overexpression is associated with favorable outcome in diffuse large B-cell lymphoma patients in the rituximab era

Sotirios G. Papageorgiou2nd Department of Internal Medicine, Propaedeutic, Hematology Unit, School of Medicine, National and Kapodistrian University of Athens, “Attikon” University General Hospital, Haidari, Greece; Correspondence[email protected]

Christos K. KontosDepartment of Biochemistry and Molecular Biology, University of Athens, Athens, Greece;

Periklis G. Foukas2nd Department of Pathology, School of Medicine, National and Kapodistrian University of Athens, “Attikon” University Hospital, Haidari, Greece

Eleni Panopoulou2nd Department of Pathology, School of Medicine, National and Kapodistrian University of Athens, “Attikon” University Hospital, Haidari, Greece

Diamantina Vasilatou2nd Department of Internal Medicine, Propaedeutic, Hematology Unit, School of Medicine, National and Kapodistrian University of Athens, “Attikon” University General Hospital, Haidari, Greece;

Stamatia-Maria RaptiDepartment of Biochemistry and Molecular Biology, University of Athens, Athens, Greece;

Konstantinos Gkontopoulos2nd Department of Internal Medicine, Propaedeutic, Hematology Unit, School of Medicine, National and Kapodistrian University of Athens, “Attikon” University General Hospital, Haidari, Greece;

Efthimia Bazani2nd Department of Internal Medicine, Propaedeutic, Hematology Unit, School of Medicine, National and Kapodistrian University of Athens, “Attikon” University General Hospital, Haidari, Greece;

Ioannis G. Panayiotides2nd Department of Pathology, School of Medicine, National and Kapodistrian University of Athens, “Attikon” University Hospital, Haidari, Greece

George Dimitriadis2nd Department of Internal Medicine, Propaedeutic, Hematology Unit, School of Medicine, National and Kapodistrian University of Athens, “Attikon” University General Hospital, Haidari, Greece;

Andreas ScorilasDepartment of Biochemistry and Molecular Biology, University of Athens, Athens, Greece;

Vasiliki Pappa2nd Department of Internal Medicine, Propaedeutic, Hematology Unit, School of Medicine, National and Kapodistrian University of Athens, “Attikon” University General Hospital, Haidari, Greece;

show all

BCL2L12 protein overexpression is associated with favorable outcome in diffuse large B-cell lymphoma patients in the rituximab era

Supplementary Figure 1. Representative pictures (x40) of anti-BCL2L12 immunohistochemistry in two cases of DLBCL, with (a) low-moderate and (b) strong cytoplasmic staining in neoplastic cells.

Supplementary Table III. Distribution of the numerical variables in the cohort of DLBCL patients treated with R-CHOP.

Supplementary Table II. Immunohistochemistry results for the protein markers used in the current study.

Supplementary Table I. Clinicopathological characteristics of the study population.

ICMJE Form for Disclosure of Potential Conflicts of Interest

ICMJE Form for Disclosure of Potential Conflicts of Interest

ICMJE Form for Disclosure of Potential Conflicts of Interest

ICMJE Form for Disclosure of Potential Conflicts of Interest

ICMJE Form for Disclosure of Potential Conflicts of Interest

ICMJE Form for Disclosure of Potential Conflicts of Interest

ICMJE Form for Disclosure of Potential Conflicts of Interest

ICMJE Form for Disclosure of Potential Conflicts of Interest

ICMJE Form for Disclosure of Potential Conflicts of Interest

ICMJE Form for Disclosure of Potential Conflicts of Interest

ICMJE Form for Disclosure of Potential Conflicts of Interest

ICMJE Form for Disclosure of Potential Conflicts of Interest

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

BCL2L12 protein overexpression is associated with favorable outcome in diffuse large B-cell lymphoma patients in the rituximab era

Supplementary Figure 1. Representative pictures (x40) of anti-BCL2L12 immunohistochemistry in two cases of DLBCL, with (a) low-moderate and (b) strong cytoplasmic staining in neoplastic cells.

Supplementary Table III. Distribution of the numerical variables in the cohort of DLBCL patients treated with R-CHOP.

Supplementary Table II. Immunohistochemistry results for the protein markers used in the current study.

Supplementary Table I. Clinicopathological characteristics of the study population.

ICMJE Form for Disclosure of Potential Conflicts of Interest

ICMJE Form for Disclosure of Potential Conflicts of Interest

ICMJE Form for Disclosure of Potential Conflicts of Interest

ICMJE Form for Disclosure of Potential Conflicts of Interest

ICMJE Form for Disclosure of Potential Conflicts of Interest

ICMJE Form for Disclosure of Potential Conflicts of Interest

ICMJE Form for Disclosure of Potential Conflicts of Interest

ICMJE Form for Disclosure of Potential Conflicts of Interest

ICMJE Form for Disclosure of Potential Conflicts of Interest

ICMJE Form for Disclosure of Potential Conflicts of Interest

ICMJE Form for Disclosure of Potential Conflicts of Interest

ICMJE Form for Disclosure of Potential Conflicts of Interest

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date